News search

A new study led by the CNIC has identified imidazole propionate (ImP), a metabolite produced by gut bacteria, as a driver of atherosclerosis— as a driver of atherosclerosis, the disease behind most heart attacks and strokes

CNIC researchers have uncovered the evolutionary logic of the OxPhos system—the cell’s “engine”—and developed a tool to detect mutations that cause mitochondrial disease

This new tool will advance the development of treatments for congenital muscle diseases and cardiomyopathies. 

A team from the CNIC has discovered the key role of conventional type 1 dendritic cells (cDC1) in atherosclerosis and has developed an experimental therapy with immunosuppressive nanoparticles that slows the progression of the disease in animal models.

Dr. Joseph Hill holds the James T. Willerson, M.D., Chair in Cardiovascular Disease and the Frank M. Ryburn Jr. Chair in Cardiac Research at the University of Texas Southwestern Medical Center

Prof. Daniel Ketelhuth leads a research team at the University of Southern Denmark

A CNIC team has developed an innovative gene therapy strategy for arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and deadly inherited condition that particularly affects young men

The discovery, published in Nature, opens the path to new strategies for treating skin diseases and immunological disorders, with special potential for the treatment of inflammation, diabetes, and age-related conditions